21 May 2013
Keywords: genentech, progress, breast, cancer, antibody, without, releasing
Article | 29 December 1997
Without releasing any details, Genentech has said it has encouragingpreliminary data from its Phase III trials program for Herceptin (trastuzumab), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.